Clinical impact of the metabolic phenotype of prostate cancer: role of monocarboxylate transporters (MCTs)

Ítems similars

• Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer
  per: Pértega-Gomes, Nelma, et al.
  Publicat: (2011)
• Lactate Transporters in the Context of Prostate Cancer Metabolism: What Do We Know?
  per: Nelma Pértega-Gomes, et al.
  Publicat: (2014-10-01)
• Lactate Transporters in the Context of Prostate Cancer Metabolism: What Do We Know?
  per: Pértega-Gomes, Nelma, et al.
  Publicat: (2014)
• Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets
  per: Miranda-Gonçalves, Vera, et al.
  Publicat: (2013)
• A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy
  per: Pertega‐Gomes, Nelma, et al.
  Publicat: (2015)